Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multicenter, Observational Long-term Study Evaluating the Safety, Tolerability, and Efficacy of Treatment of SM04690 or Placebo Previously Injected in the Target Knee Joint of Subjects With Moderately to Severely Symptomatic Osteoarthritis

Next Previous
X
Search
Trial Profile

A Phase 3, Multicenter, Observational Long-term Study Evaluating the Safety, Tolerability, and Efficacy of Treatment of SM04690 or Placebo Previously Injected in the Target Knee Joint of Subjects With Moderately to Severely Symptomatic Osteoarthritis

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 10 Jan 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lorecivivint (Primary)
  • Indications Osteoarthritis
  • Focus Adverse reactions
  • Sponsors Biosplice Therapeutics; Samumed

    • Most Recent Events

    • 09 Nov 2021 Status has been changed to discontinued, according results presented at the ACR Convergence 2021.
    • 28 Aug 2021 Results presented at the 2021 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases
    • 05 Jun 2021 Results of post-hoc efficacy analysis from three clinical studies: NCT02951026, NCT02536833 and NCT03122860 presented at the 22nd Annual Congress of the European League Against Rheumatism

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top